KATZUNG'S BASIC AND
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is reviewing information about a medication that
recently received regulatory approval. Which statement best
reflects the purpose of post-marketing surveillance?
A. It determines the maximum tolerated dose before human
use.
B. It identifies rare or delayed adverse effects after widespread
clinical use.
C. It establishes the drug's chemical structure.
D. It replaces preclinical laboratory testing.
Correct Answer: B
Rationale:
Post-marketing surveillance monitors medications after
approval to identify uncommon, long-term, or delayed adverse
effects that may not have been detected during clinical trials.
Option A describes activities associated with early clinical
development. Option C occurs during drug discovery. Option D
is incorrect because preclinical testing remains an essential step
before human studies.
Question 2
A nurse is educating a client about generic medications. Which
statement by the nurse is most accurate?
,A. Generic medications must demonstrate comparable quality
and expected therapeutic performance.
B. Generic medications always have different mechanisms of
action than brand-name drugs.
C. Generic medications are prohibited from containing inactive
ingredients.
D. Generic medications are approved without evidence of
manufacturing quality.
Correct Answer: A
Rationale:
Approved generic medications are expected to meet standards
for quality, manufacturing, and therapeutic performance
comparable to the reference product. Option B is incorrect
because generics contain the same active ingredient and
mechanism of action. Option C is incorrect because inactive
ingredients may differ. Option D is incorrect because
manufacturing quality standards remain essential for approval.
Question 3
A nurse is participating in a clinical trial and notices a
participant developing unexpected symptoms. What is the
nurse's priority action?
, A. Encourage the participant to continue the study without
reporting symptoms.
B. Document the symptoms and promptly report them
according to the study protocol.
C. Wait until the next scheduled visit before informing the
research team.
D. Remove the participant from the study without notifying
investigators.
Correct Answer: B
Rationale:
Prompt documentation and reporting of suspected adverse
events protects participant safety and preserves study integrity.
Option A delays appropriate evaluation. Option C may
jeopardize participant safety. Option D exceeds the nurse's
authority unless immediate emergency action is required and
should still involve appropriate notification.
Question 4
A nurse is explaining why a medication failed to produce the
expected therapeutic effect in one client but worked well in
another. Which concept best explains this difference?
A. Individual variability in drug response
B. Medication expiration date
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is reviewing information about a medication that
recently received regulatory approval. Which statement best
reflects the purpose of post-marketing surveillance?
A. It determines the maximum tolerated dose before human
use.
B. It identifies rare or delayed adverse effects after widespread
clinical use.
C. It establishes the drug's chemical structure.
D. It replaces preclinical laboratory testing.
Correct Answer: B
Rationale:
Post-marketing surveillance monitors medications after
approval to identify uncommon, long-term, or delayed adverse
effects that may not have been detected during clinical trials.
Option A describes activities associated with early clinical
development. Option C occurs during drug discovery. Option D
is incorrect because preclinical testing remains an essential step
before human studies.
Question 2
A nurse is educating a client about generic medications. Which
statement by the nurse is most accurate?
,A. Generic medications must demonstrate comparable quality
and expected therapeutic performance.
B. Generic medications always have different mechanisms of
action than brand-name drugs.
C. Generic medications are prohibited from containing inactive
ingredients.
D. Generic medications are approved without evidence of
manufacturing quality.
Correct Answer: A
Rationale:
Approved generic medications are expected to meet standards
for quality, manufacturing, and therapeutic performance
comparable to the reference product. Option B is incorrect
because generics contain the same active ingredient and
mechanism of action. Option C is incorrect because inactive
ingredients may differ. Option D is incorrect because
manufacturing quality standards remain essential for approval.
Question 3
A nurse is participating in a clinical trial and notices a
participant developing unexpected symptoms. What is the
nurse's priority action?
, A. Encourage the participant to continue the study without
reporting symptoms.
B. Document the symptoms and promptly report them
according to the study protocol.
C. Wait until the next scheduled visit before informing the
research team.
D. Remove the participant from the study without notifying
investigators.
Correct Answer: B
Rationale:
Prompt documentation and reporting of suspected adverse
events protects participant safety and preserves study integrity.
Option A delays appropriate evaluation. Option C may
jeopardize participant safety. Option D exceeds the nurse's
authority unless immediate emergency action is required and
should still involve appropriate notification.
Question 4
A nurse is explaining why a medication failed to produce the
expected therapeutic effect in one client but worked well in
another. Which concept best explains this difference?
A. Individual variability in drug response
B. Medication expiration date
